Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis) TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring…
MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence…
Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for…
TORONTO and VANCOUVER, CANADA (January 12, 2016) — A novel drug therapy to reduce the severity and frequency of hypoglycemic (low blood sugar) episodes in people with diabetes is being…
MLA48 leads ConferenceCloud pre-seed round in cooperation with UTEST TORONTO, CANADA (January 11, 2016) — MLA48, Canada’s first angel investment fund committed to providing a 48-hour turnaround on investment decisions,…
2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI's portfolio in…
UTEST graduate eQOL has received $350,000 from the Ontario Government to support patients managing their kidney dialysis at home. eQOL's solutions use mobile tablets technology to support patients in managing…
TORONTO and SAN DIEGO (December 8, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that positive results…
“In a project spearheaded by PhD candidate Reza Nosrati, U of T researchers are trying to learn more about the way sperm cells move — something that could benefit those using in vitro fertilization (IVF),” writes Daniel Otis in “Sperm show U of T researchers a new trick: slithering” published in the Toronto Star on November 13, 2015.
MaRS Innovation is working with Professor David Sinton, Nosrati and the university’s Innovations and Partnerships Office to commercialize the technology for the human sperm selection markets, including intellectual property strategy and patent filing, and securing industry partners and collaborators.
TORONTO and SAN DIEGO (November 19, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for marizomib to treat patients with malignant glioma.
Malignant glioma is an aggressive form of brain cancer for which there is a significant unmet need in current treatments due to the disease’s poor prognosis. Triphase is evaluating marizomib, a novel and highly potent proteasome inhibitor, in combination with bevacizumab in patients with recurrent glioblastoma.
Orphan drug designation is granted by the FDA Office of Orphan Products Development (OOPD) to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the United States.
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca